Development and Quality Control of a Population Pharmacokinetic Model Library for Caspofungin

• Main Authors: Nuo Xu (Author), Yufei Shi (Author), Yixue Wang (Author), Wenyao Mak (Author), Wenyu Yang (Author), Kar Weng Ng (Author), Yue Wu (Author), Zhijia Tang (Author), Qingfeng He (Author), Gangfeng Yan (Author), Xiaoqiang Xiang (Author), Xiao Zhu (Author)
• Format: Book
• Published: MDPI AG, 2024-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 10.3390/pharmaceutics16060819; 1999-4923
• Keywords: caspofungin; individualized dosing; population pharmacokinetics; model library; Pharmacy and materia medica; RS1-441
• Source: Pharmaceutics, Vol 16, Iss 6, p 819 (2024)

Background: Caspofungin is an echinocandin antifungal agent commonly used as the first-line therapy for invasive candidiasis, salvage therapy for invasive aspergillosis, and empirical therapy for presumed fungal infections. Pharmacokinetic (PK) variabilities and suboptimal exposure have been reported for caspofungin, increasing the risk of insufficient efficacy. Objective: This work aimed to develop a caspofungin population pharmacokinetic (popPK) library and demonstrate its utility by assessing the probability of target attainment across diverse settings. Methods: We established a caspofungin popPK model library following a rigorous literature review, re-implementing selected models in R with rxode2. Quality control procedures included a comparison of different studies and assessing covariate impacts. Model libraries were primarily used to perform Monte Carlo simulations to estimate target attainment and guide personalized dosing in Candida infections. Results: A total of 13 models, one- or two-compartment models, were included. The most significant covariates were body size (weight and body surface area), liver function, and albumin level. The results show that children and adults showed considerable differences in pharmacokinetics. For <i>C. albicans</i> and <i>C. parapsilosis</i>, none of the populations achieved a PTA of ≥90% at their respective susceptible MIC values. In contrast, for <i>C. glabrata</i>, 70% of the adult studies reached a PTA of ≥90%, while all pediatric studies achieved the same PTA level. Conclusion: At the recommended dosage, adult patients showed notably lower exposure to caspofungin compared to pediatric patients. Considering body size, liver function, and serum albumin is crucial when determining caspofungin dosage regimens. Furthermore, further research is required to comprehensively understand the pharmacokinetics of caspofungin in pediatric patients.